Testing Experimental Pancreatic Cancer Treatment

Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers

This pilot clinical trial studies the use of integrin alpha-v-beta [18F]-R01-MG-F2 Positron Emission Tomography/Computed Tomography (PET/CT) and Positron Emission Tomography-Magnetic Resonance Imaging in (PET/MRI) in measuring response in patients with pancreatic cancer and healthy volunteers. Integrins, such as integrin alpha-v-beta-6 (avb6), are a family of membrane receptors that are overexpressed on the cell surface of pancreatic cancers. [18F]-R01-MG-F2 targets avb6, which may improve early detection of and better stratify treatment options for patients with pancreatic cancer.

Pharmaceutical medication involved
Patients and healthy individuals accepted

Diagnostic Test - Computed Tomography

Undergo CT scan

Laboratory Biomarker Analysis

Correlative studies

Diagnostic Test - PET/MRI scan

Undergo PET/MRI scan

Drug - [18F]FP-R01-MG-F2

radioactive tracer

Detection of Integrin Alpha-v-Beta 6 in Pancreatic Cancer With [18F]-R01-MG-F2: a First in Human Study